NCAM1 and acute myeloid leukemia: Furthermore, we confirmed the prognostic impact of CD56, as a marker associated with higher blast counts (by both CM and FC analysis) and AML-like mutations patterns (Group 7 and DNMT3A mutations), and the correlation between lower CD117 expression and Bersanelli group 2, characterized by dismal outcome [12], while we did not find any correlations between CD7 and adverse outcome, according to Font et al.